Receh.in - PT Industri Jamu Dan Farmasi Sido Muncul Tbk, also known as Sido Muncul, recorded sales of IDR 3.86 trillion in 2022, a decrease from the previous year's IDR 4.02 trillion. Meanwhile, the cost of sales was IDR 1.70 trillion, lower than the IDR 1.73 trillion in 2021.
In its 2022 financial report, Sido Muncul posted a gross profit of IDR 2.16 trillion, a decline from IDR 2.28 trillion in 2021. The company's operating profit also decreased to IDR 1.39 trillion, down from IDR 1.57 trillion.
Sido Muncul's full-year net profit in 2022 amounted to IDR 1.10 trillion, a decrease of 12.3% compared to the IDR 1.26 trillion in 2021. However, according to the company's official statement, the net profit in the fourth quarter of 2022 increased by 40% compared to the third quarter of 2022.
As a result, the basic earnings per share attributable to the parent entity for 2022 was IDR 36.82, a drop from the IDR 42.28 in 2021. The company's total assets as of December 31, 2022 were IDR 4.08 trillion, liabilities were IDR 575.96 billion, and equity was IDR 3.50 trillion.
SIDO Profile
PT Industri Jamu Dan Farmasi Sido Muncul Tbk, also known as Sido Muncul, is a leading Indonesian company in the traditional herbal medicine and pharmaceutical industry. With a long history dating back to the 1940s, the company has established itself as a trusted brand in the Indonesian market, offering a range of high-quality herbal remedies and pharmaceutical products to its customers.
Sido Muncul operates a large-scale production facility, where it produces its products in strict adherence to international standards and regulations. The company is committed to providing consumers with safe and effective products, and invests heavily in research and development to ensure that its products meet the highest quality standards.
The company's product line includes traditional herbal remedies, health supplements, and over-the-counter medications. The products are sold through a variety of channels, including retail stores, pharmacies, and online platforms. Sido Muncul's distribution network reaches across Indonesia, making its products accessible to consumers in even the most remote areas.
In recent years, Sido Muncul has expanded its operations internationally, exporting its products to countries in Southeast Asia, the Middle East, and Africa. The company's commitment to quality, innovation, and customer satisfaction has helped it to build a strong reputation as a leader in the herbal medicine and pharmaceutical industries.
Sido Muncul is publicly traded on the Indonesian Stock Exchange, and its shares are widely held by a range of investors, including institutional and retail investors. With its strong financial performance, commitment to quality and customer satisfaction, and its long history of success, Sido Muncul is poised for continued growth and success in the years to come.
0 Komentar